PTC Therapeutics Inc.（PTCT）今日盘中大涨5.03%，引发市场广泛关注。这一涨幅主要源于公司发布的2025年第一季度财报及未来发展前景。
财报显示，PTC Therapeutics第一季度收入达1.9亿美元，其中杜氏肌营养不良（DMD）业务贡献1.34亿美元，表现强劲。公司将2025年全年收入指导范围缩小至6.5亿至8亿美元。此外，公司财务状况稳健，截至2025年3月31日的现金、现金等价物和有价证券总额高达27亿美元，较去年同期的14亿美元大幅增加。
投资者对PTC Therapeutics的新药SUFIANCE（Cefiance）在欧洲获得积极意见反应热烈。公司计划在未来12个月内在25个市场推出SUFIANCE，包括德国、美国和日本。尽管Emflaza面临仿制药竞争，但公司表示其品牌忠诚度依然强劲。管理层对公司未来发展前景充满信心，这进一步推动了股价上涨。分析师们也对公司的财务表现和新产品发布表示赞赏，整体情绪积极。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.